Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.68 |
| ▸ | CNR1 | P21554 | 11/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2506054 | 0.93 | CNR2 (0.67) | CNR2CNR1GLAKMT2ATDP1 | |
| SCHEMBL2511405 | 0.83 | CNR2 (0.70) | CNR2CNR1 | |
| SCHEMBL12284589 | 0.83 | CNR2 (0.55) | CNR2CNR1 | |
| SCHEMBL12197619 | 0.82 | CNR2 (1.00) | CNR2CNR1 | |
| Hydrochloric Acid SCHEMBL2511051 | 0.81 | CNR2 (0.98) | CNR2CNR1 | |
| SCHEMBL2554012 | 0.81 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL12197621 | 0.80 | CNR2 (0.90) | CNR2CNR1 | |
| SCHEMBL12197620 | 0.80 | CNR2 (0.90) | CNR2CNR1 | |
| Hydrochloric Acid SCHEMBL2509585 | 0.80 | CNR2 (0.90) | CNR2CNR1 | |
| SCHEMBL14321181 | 0.80 | CNR2 (0.52) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552921-B1 | PURINE COMPOUNDS | LILLY CO ELI (US) | 2015-10-07 | — | — | EP | disclosed |
| US-8759360-B2 | Purine compounds | ELI LILLY AND COMPANY (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759360-B2 | Purine compounds | ELI LILLY AND COMPANY (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759360-B2 | Purine compounds | ELI LILLY AND COMPANY (US) | 2014-06-24 | — | — | US | disclosed |
| WO-2011123372-A1 | PURINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245255-A1 | PURINE COMPOUNDS | ELI LILLY AND COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110245255-A1 | PURINE COMPOUNDS | ELI LILLY AND COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110245255-A1 | PURINE COMPOUNDS | ELI LILLY AND COMPANY | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245255-A1 | PURINE COMPOUNDS | P2RX1, P2RX3, P2RX7 | CNR2 380/4885CNR1 465/4885GLA 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.